Skip to main
PSNL
PSNL logo

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 70%
Buy 10%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc exhibited a notable increase in gross margin to 27.1% in 4Q24, reflecting a 50 basis point improvement year-over-year, primarily attributed to a favorable customer mix and significant growth in biopharma testing and services, which rose by 59% to $51 million in 2024. The company has also shown an uptick in clinical test volumes, with 1,441 NeXT Dx and NeXT Personal tests completed in 4Q24, marking a 53% increase compared to the prior quarter. Furthermore, the increase in revenue from minimal residual disease (MRD) testing, which grew over 50% in 2024, highlights strong demand in the market and reinforces the successful partnership between Personalis and Tempus.

Bears say

Personalis Inc. has experienced a decline in revenue, with fourth-quarter total revenues decreasing by 15% year-over-year to $16.8 million, which fell below both consensus expectations and the company's previous growth rates. Additionally, the company faces significant risks, including slower adoption rates of its new products, heightened competition within its market, and a marked decline in revenue from the VA MVP program, which dropped from $4.4 million in the preceding quarter to just $0.2 million. The outlook for future growth appears pessimistic, with projections for 2025 total revenues revised downward to $86.9 million, significantly lower than earlier estimates, reflecting weak performance in both biopharma and clinical diagnostics segments.

Personalis Inc (PSNL) has been analyzed by 10 analysts, with a consensus rating of Buy. 70% of analysts recommend a Strong Buy, 10% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 10 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.